MAP2K7 and acral lentiginous melanoma: The data from this study may reflect the natural history of acral melanoma because only 1 out of 112 patients had received BRAF/MEK inhibitor treatment and the majority of our cohort, thus, had not undergone BRAF-targeted therapy.